logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On March 31st, STANCHART (02888) spent 15.3417 million pounds to repurchase 984,000 shares.

date
16:57 01/04/2026
avatar
GMT Eight
Standard Chartered Group (02888) announced that the company repurchased 984,000 shares at a cost of 15.3417 million pounds on March 31, 2026.
STANCHART (02888) announced that the company repurchased 984,000 shares at a cost of 15.3417 million pounds on March 31, 2026.
Related Articles
HK Stock
NEWAY GROUP (00055): Zhang Yushan appointed as the new company secretary.
HK Stock
GLORIOUS PPT H(00845): Property units selling and delivering total construction area exceeding 70,000 square meters in 2025.
HK Stock
SINOMAB BIO-B (03681): The first patient in China with atopic dermatitis completes Phase 2 clinical trial of SM17 treatment.
NEWAY GROUP (00055): Zhang Yushan appointed as the new company secretary.
HK Stock
GLORIOUS PPT H(00845): Property units selling and delivering total construction area exceeding 70,000 square meters in 2025.
HK Stock
SINOMAB BIO-B (03681): The first patient in China with atopic dermatitis completes Phase 2 clinical trial of SM17 treatment.
HK Stock
RECOMMEND
The “Google Panic” In Memory Stocks: New Cycle Dynamics Beneath Technological Headlines
The “Google Panic” In Memory Stocks: New Cycle Dynamics Beneath Technological Headlines
icon
01/04/2026
Price Increase Cycle Begins, Semiconductor Industry Enters New Stage Of Rising Volume And Value
Price Increase Cycle Begins, Semiconductor Industry Enters New Stage Of Rising Volume And Value
icon
01/04/2026
When Will Hong Kong Stocks Reach Their Low Point?
When Will Hong Kong Stocks Reach Their Low Point?
icon
01/04/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.